Report Archive
All Research
Page 5 of 43 · 1027 reports
44/100
RBC Bearings: The Moat Is Real, but the Price Already Assumes the Aerospace-Defense Story Is Finished
RBC Bearings is a niche U.S. manufacturer of qualification-protected precision bearings, engineered components, and fluid-control systems for aerospace, defense, and industrial platforms, shaped over three decades by founder-CEO Michael Hartnett's 29-deal acquisition program. Fiscal 2026 revenue reached $1.87 billion as Aerospace & Defense sales grew 32.9% against 3.8% Industrial growth, backlog surged to $2.3 billion, and the stock re-rated toward premium defense-compounder multiples (about 48x adjusted EPS) even as owner-earnings yield fell near 1.8%, below the 4.27% 10-year Treasury yield. Rating Watch: an excellent, moat-protected compounder, but today's price already discounts years of successful mix conversion, leaving the ideal buy zone at $290-340.
41/100
Leonardo: A Re-Rating With Real Earnings Behind It, Priced Like the Quality Gap to BAE and Thales Is Already Closed
Leonardo S.p.A. is Italy's state-influenced aerospace and defense group, whose profit engine sits in defense electronics and helicopters and is now backed by a €56.8 billion Q1 2026 order backlog. FY2025 orders reached €23.8 billion and EBITA €1.75 billion as Europe's rearmament cycle drove a sharp re-rating, yet the stock now trades near a 30.9x trailing P/E, roughly matching cleaner peers such as Thales and BAE Systems even though Leonardo still carries a persistent state-governance discount and weaker aerostructures drag. Rating Hold: order momentum and cash generation are real, but the price already assumes much of the quality convergence that has not yet fully happened, leaving the ideal buy zone at €39-43.
31/100
X-Energy: Real Nuclear-Licensing Progress, Priced Like a Decade of Milestones Is Already Won
X-Energy is a newly IPO'd, pre-commercial advanced-nuclear reactor and fuel developer, monetizing the Xe-100 reactor design and TRISO-X fuel manufacturing through DOE cost-share funding and development-stage services rather than power sales. Rating Watch: at $18.32 the stock already discounts a meaningful share of first-of-a-kind execution success, with an ideal buy zone of $9-11 requiring either a real price pullback or bankable proof that the Seadrift project and TX-1 fuel plant convert from milestones into commercial economics.
46/100
Thales: A Genuine Defence-Electronics Quality Compounder, Priced Like the Best Case Is Already Locked In
Thales is a French defence-electronics and aerospace group whose 2025 sales reached €22.1 billion with free operating cash flow of €2.58 billion, now expanding into naval robotics through the Exail acquisition after absorbing Germany's F126 contract termination. Rating Hold: at €241.10 the stock already trades above its own historical average multiple, pricing in continued defence-cycle strength and a smooth Exail integration, leaving the ideal buy zone at €160-170.
46/100
Soitec: The AI-Photonics Turn Is Real, But the Price Already Assumes It Wins
Soitec designs and manufactures engineered semiconductor substrates—RF-SOI for mobile radios, FD-SOI for automotive and industrial computing, and increasingly Photonics-SOI for AI optical interconnects—competing on architecture-specific performance rather than commodity wafer volume. Fiscal 2026 revenue fell 34% to €591.8 million and the company swung to a €220 million net loss, yet Edge & Cloud AI revenue kept growing and the shares have since risen more than fivefold on AI-photonics enthusiasm, pushing trailing EV/sales to about 7.2x with an owner-earnings yield below the French government bond yield. Rating Watch: real technology and cash generation, but no margin of safety until shares fall back toward the €60-75 ideal buy zone.
41/100
Regal Rexnord: A Genuine Industrial Transformation, Already Priced Past Its Margin of Safety
Regal Rexnord is a US industrial motion and power-transmission supplier reshaped by the 2021 Rexnord PMC merger and 2023 Altra acquisition, now generating $5.93 billion of 2025 sales across automation, power-transmission, and power-efficiency segments. The core tension is between a genuinely improved portfolio with real data-center momentum (about $735 million of Q4 2025 ePOD-related orders) and a robotics narrative management itself deflated (just over $1 million of Q1 2026 humanoid-actuation orders versus $40 million for all of 2025), against a stock already trading near 36x trailing earnings with a conservative fair value of about $176. Rating Hold: a real industrial transformation, but today's $229.36 price leaves no margin of safety, with expected annualized returns ranging from about -14% to +7% across scenarios.
47/100
Kongsberg Gruppen: A Genuine Defense Franchise Priced for a Decade of Perfect Execution
Kongsberg Gruppen is Norway's post-spin defense and ocean-space technology group, having demerged Kongsberg Maritime in April 2026 to focus on air-defense and missile systems alongside a smaller Discovery segment. The core tension is between a genuinely strong business, a record NOK 152.0 billion backlog with disciplined framework-agreement accounting, and a stock priced at roughly 9.1x trailing sales and about 70x trailing earnings that already assumes years of near-flawless execution toward management's bold 2029/2033 revenue targets. Rating Watch: a real defense franchise, but today's NOK 328.1 price leaves little margin of safety, with expected annualized returns ranging from about -17% to +6% across scenarios.
33/100
Endeavour Silver: The Three-Mine Platform Is Real, But Silver's Rally Is Doing Much of the Work
Endeavour Silver is a Mexico-and-Peru underground silver miner reshaped by the Terronera mine ramp-up, the Kolpa acquisition, and the Bolañitos divestiture. Q1 2026 revenue jumped to $209.7 million and net earnings to $64.9 million, but results were flattered by a one-time Bolañitos sale gain and by spot silver running far above the company's own $36-per-ounce planning assumption. Rating Hold: the three-mine transformation is real, but at $8.56 the stock offers little margin of safety until shares fall toward the $6.0-6.6 conservative range.
36/100
Aeva Technologies: A Genuine LiDAR Re-Rating, Priced As If 2028 Is Already Won
Aeva builds FMCW 4D LiDAR sensors and perception software for automotive, trucking, and industrial customers, converting technical differentiation into early commercial wins like Nikon and NVIDIA Hyperion. Q1 2026 revenue grew 86% to $6.3 million but stayed service-heavy, while the stock's roughly $1.64 billion valuation already prices in 2028 production ramps that remain contractually unproven. Rating Watch: real technology validation, but no margin of safety until shares fall toward the $8-10 conservative range.
43/100
Hwatsing Technology: A Real CMP Champion, Priced as if the Platform Story Is Already Won
Hwatsing Technology (688120.SHG) is China's domestic leader in chemical-mechanical-polishing equipment, expanding from a single CMP tool into a broader semiconductor-equipment and services platform. 2025 revenue grew 36.5% to CNY 4.65 billion and net profit rose to CNY 1.08 billion, but operating cash flow fell 30.7% as inventory and receivables absorbed cash, even as the stock trades near 120.6x trailing earnings around the 99th percentile of its own valuation history. Rating Avoid: the CMP franchise and platform ambition are real, but the price already assumes a platform future the segment disclosures cannot yet prove, with the ideal buy zone at CNY 110 to 125.
34/100
Pinggao Electric: The Cleanest UHV Switchgear Play, But Orders Are Not Yet Revenue
Pinggao Electric is a state-backed specialist in high-voltage and ultra-high-voltage (UHV) switchgear, with 2025 revenue of CNY 12.52 billion and net profit of CNY 1.12 billion, riding State Grid's newly enlarged CNY 4 trillion 2026-2030 capex plan and fresh tender wins of about CNY 12.23 billion in March 2026 and CNY 20.92 billion in June 2026. Rating Hold: revenue is recognized only at customer sign-off, not at tender announcement, and 2025 operating cash flow fell to CNY 0.81 billion from CNY 3.01 billion in 2024 even as profit rose, so the current CNY 17.69 price already pays a fair cycle multiple with the ideal buy zone at CNY 12.5 to 14.5.
41/100
Ouster: A Much Better Lidar Company, Priced Like the Transition Is Already Won
Ouster is a digital-lidar and perception supplier that has broadened from a single-product sensor maker into an industrial-automation and smart-infrastructure platform, with 2025 revenue of $169.4 million (up from $83.3 million in 2023) and Q1 2026 revenue of $49 million, up 49% year over year, alongside a 43% GAAP gross margin. Rating Watch: the July 2, 2026 $200 million common-stock offering at $55.22 per share confirms management will dilute shareholders whenever the stock is rich, and at the July 3 close of $49.84 the market is already paying for sustained 30%-50% growth and a clean path to profitability, leaving the ideal buy zone at $20 to $22.
40/100
DSM-Firmenich: A Genuine Portfolio Cleanup, Already Priced for the Improvement to Continue
DSM-Firmenich is a Swiss-domiciled flavors, fragrances and health-ingredients platform whose 2025 continuing-operations results (sales of EUR 9.03 billion, adjusted EBITDA of EUR 1.77 billion at a 19.6% margin) show a business getting cleaner as it exits Animal Nutrition & Health to CVC for about EUR 2.2 billion, while Perfumery & Beauty carries the group with 8% like-for-like growth in the first quarter of 2026 even as Taste, Texture & Health and Health, Nutrition & Care remain uneven. Rating Hold: the portfolio has genuinely improved faster than the market expected a year ago, but at EUR 85 the price already reflects a fair share of that cleanup, with the ideal buy zone at EUR 64 to 70.
31/100
Fresnillo: A Genuine Re-Rating, But the Price Already Assumes the Hard Part Is Done
Fresnillo is the world's largest primary silver producer and one of Mexico's largest gold producers, whose 2025 results (adjusted revenue of US$4.65 billion, EBITDA of US$2.80 billion, and net cash of US$1.92 billion) were driven mainly by a favorable metals tape rather than a structural improvement, even as the company cut 2026 guidance to 42-46.5 million ounces of silver and 500-550 thousand ounces of gold after grade and mine-plan setbacks at Fresnillo, Saucito and Herradura. Rating Hold: high cash generation and scarce silver exposure are real, but at £29.22 the price already discounts favorable metals while execution risk, Mexico concentration and Peñoles' 74.99% control remain unresolved, with the ideal buy zone at £15 to £17.
42/100
ACM Research Shanghai: A Genuine Platform Story, Priced for Zero Margin of Safety
ACM Research Shanghai is the Shanghai-listed operating core of a dual-listed Chinese semiconductor wet-process equipment group, whose U.S. parent ACM Research (ACMR.US) holds a 73.6% stake but trades at a steep discount to the A-share line's implied look-through value. 2025 revenue rose 20.8% to CNY 6.79 billion and net profit rose 21.1% to CNY 1.40 billion, but operating cash flow collapsed to just CNY 239 million from CNY 1.22 billion and turned negative in the first quarter of 2026, even as the stock trades near 130 times trailing earnings and about 180% above the parent-implied look-through value. Rating Watch: the platform story is real, but the price already assumes near-flawless execution while cash conversion has weakened, with the ideal buy zone at CNY 140 to 150.
39/100
Saipem: The Offshore Repair Is Real, but the Subsea7 Merger Remains Unresolved
Saipem is an Italian offshore engineering, construction and drilling contractor whose earnings recovery is now driven mainly by its Asset Based Services offshore segment, with a pending merger with Subsea7 standing as the central event-driven value lever. 2025 revenue rose to 15.5 billion EUR and EBITDA grew 29.1% to 1.716 billion EUR while pre-IFRS 16 net cash climbed to 999 million EUR, yet reported backlog slipped from 34.1 billion EUR to 29.7 billion EUR and Australia's antitrust regulator pushed the Subsea7 deal into a Phase 2 review on 2026-07-03. Rating Hold: the offshore repair is real and the balance sheet is strong, but the current price already discounts much of that progress while merger-approval risk stays unresolved, with the ideal buy zone at 3.5 to 3.9 EUR.
U.S. Market Close Daily | 2026-07-03
U.S. cash markets were closed for the Independence Day observance, leaving the latest tape in sector rotation with Dow strength, Nasdaq/chip weakness, and softer labor data easing rate pressure.
35/100
Stellantis: Deep Discount, Real Net Cash, and a Turnaround Still on Trial
Stellantis is a global multi-brand automaker (Jeep, Ram, Peugeot, Fiat and more) whose economics hinge on North America, entering 2026 after a 22.3 billion EUR net loss in the 2025 reset year. Industrial net cash of 9.5 billion EUR and Q1 2026's return to growth (revenue up 6%, adjusted operating margin 2.5%) buy the turnaround time, yet at 5.81 USD the shares sit between the ideal-buy zone and fair value while warranty scars and tariffs keep normalized earning power suspect. Rating Watch: deep discount and net cash create upside, but the turnaround still needs proof in North America, warranty costs, and cash generation.
31/100
SSR Mining: Cash-Rich After the Çöpler Exit, With the Real Test Still Ahead
SSR Mining is an Americas-focused gold-and-silver producer running four mines (Marigold, Cripple Creek & Victor, Seabee, Puna), guiding 450,000–535,000 gold-equivalent ounces for 2026 after completing its exit from Türkiye. The June 24, 2026 Çöpler sale converted the portfolio's biggest source of risk into about 1.49 billion USD of cash, implying at least roughly 1.82 billion USD pro forma, yet at 30.31 USD the stock already prices in much of the de-risking while the larger capital-allocation test is still ahead. Rating Hold: the balance sheet is far better after Çöpler, but the current price discounts much of that cleanup before redeployment is fully proven.
43/100
Legend Biotech: CARVYKTI Is a Real Franchise, Self-Funding Is Still Unproven
Legend Biotech is a commercial-stage cell-therapy company whose economics are dominated by CARVYKTI, the BCMA CAR-T it shares equally with Johnson & Johnson outside Greater China while bearing and retaining 70% in Greater China. Collaboration revenue reached 944.8 million USD in 2025 and quarterly CARVYKTI trade sales hit 597 million USD in Q1 2026, up 62% year over year, yet the same quarter still showed a 54.3 million USD net loss and June 2026 brought a follow-on offering of about 226 million USD gross. Rating Hold: CARVYKTI is a real franchise, but the current price does not pay generously for single-asset concentration, shared economics, and continuing dilution risk, and new capital only gets attractive at 22 to 24 USD.
42/100
First Majestic Silver: A Better Miner After Los Gatos, No Longer a Cheap One
First Majestic is a Mexico-focused silver-and-gold miner whose earnings engine was rebuilt by the January 2025 Gatos Silver acquisition, a deal that added a 70% stake in Los Gatos, lifted scale and cost quality, and left former Gatos holders with about 38% of the company. 2025 delivered record revenue of 1.257 billion USD and free cash flow of 470.6 million USD, and Q1 2026 added 476.7 million USD of revenue with 223.5 million USD of free cash flow, yet 2026 guidance calls for lower silver output, Q1 AISC ran 29.76 USD per ounce, and the Mexican tax dispute remains unresolved. Rating Hold: Los Gatos made First Majestic a better miner, but at 17.82 USD the price already reflects much of that upgrade, and the entry only gets attractive below 16 USD.
55/100
Pharmaron Beijing: Order Momentum Returns, but the Platform Is Still Unfinished
Pharmaron Beijing is an integrated drug R&D outsourcing platform whose laboratory-services engine, RMB 8.16 billion of FY2025 revenue at a 45.1% gross margin, still funds the build-out of CMC, clinical and biologics capacity. FY2025 revenue grew 14.8% to RMB 14.10 billion while attributable profit fell 7.2% to RMB 1.66 billion on a prior-year investment-gain base, and Q1 2026 new orders grew more than 30% with CMC orders up over 50%, yet North America supplies roughly 61.8% of revenue under a sector-wide geopolitical discount. Rating Hold: a good discovery-and-chemistry franchise is funding a real but unfinished move into broader CRDMO, leaving the current CNY 29.11 price short of a margin-of-safety entry below CNY 25.
U.S. Market Close Daily | 2026-07-02
A mixed U.S. tape showed broad rotation and a Dow record as weak June hiring cooled rate-hike fears but AI hardware selling dragged the Nasdaq.
32/100
NANO Nuclear Energy: A Well-Capitalized Microreactor Option, Priced Ahead of Commercial Proof
NANO Nuclear is a pre-revenue microreactor developer, best read as a listed basket of nuclear options funded by an unusually large cash balance, with its KRONOS reactor now the lead asset in formal NRC review. Total liquidity of 568.7 million USD at March 2026 removes near-term financing stress, but there is still no product revenue and commercialization is only an early-2030s aspiration. Rating Hold: the cash pile makes permanent loss less likely, yet at 20.75 USD the price already pays for years of regulatory progress that has not yet happened.